Search | Clinical Trials Finder

Conditions: Normal, PCOS
Interventions: oral micronized progesterone suspension, Placebo; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Healthy Adult Subjects
Interventions: ONO-7746; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Peripheral Arterial Disease, Angina
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 40 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Community-acquired Infection
Interventions: GSK2251052 750 mg, GSK2251052 1500 mg, GSK2251052 1500 mg BID, GSK2251052 2250 mg, GSK2251052 3000 mg, GSK2251052 0.9% saline; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Post Traumatic Stress Disorder
Interventions: Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm; Behavioral · Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Pain, Breast Carcinoma, Peripheral Neuropathy
Interventions: Minocycline Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Pismo Beach, California • Normal, Illinois • Urbana, Illinois + 9 more

Conditions: Glaucoma
Interventions: latanoprost 0.005%, Placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Palm Beach Gardens, Florida

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aprepitant, Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Hypertension, Diabetes Type 2
Interventions: Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Disorders of Gut-brain Interaction
Interventions: Active Therapeutic acupuncture intervention, Sham therapeutic acupuncture treatment; Other
Lead sponsor: Children's Hospital of Orange County; Other
Eligibility: 8 Years to 17 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Irvine, California

Conditions: Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
Interventions: Ociperlimab, Tislelizumab, Carboplatin, Paclitaxel, Nab paclitaxel, Cisplatin, Pemetrexed, Placebo; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Los Angeles, California • Iowa City, Iowa • Las Vegas, Nevada + 8 more

Conditions: Hyperphosphatemia
Interventions: Tenapanor, Placebo, Phosphate Binder Agents; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 48
States / cities: Huntsville, Alabama • Pine Bluff, Arkansas • Beverly Hills, California + 41 more

Conditions: Bipolar Disorder (BD), Bipolar 1 Depression, rTMS, fMRI
Interventions: MagVenture MagPro TMS system, Sham Stimulation; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple System Atrophy
Interventions: rasagiline mesylate, placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 15
States / cities: Irvine, California • La Jolla, California • Sunnyvale, California + 12 more

Conditions: Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Interventions: Intravenous digoxin; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Asthma, Bronchospasm
Interventions: albuterol (Armstrong Albuterol HFA), Albuterol Sulfate (Provenetil-HFA), Placebo-HFA; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Denver, Colorado • Englewood, Colorado • Lakewood, Colorado

Conditions: Healthy Volunteers
Interventions: ketoconazole-placebo, placebo-ketoconazole; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Insomnia Disorder
Interventions: ACT-541468, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 65 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Brandon, Florida • Chicago, Illinois • Las Vegas, Nevada + 2 more

Conditions: Interstitial Cystitis
Interventions: H&P; ECG; Blood tests; voiding diary; Cystoscopy; Procedure
Lead sponsor: ICOS Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 24
States / cities: Anchorage, Alaska • Glendora, California • La Mesa, California + 20 more

Conditions: Malaria
Interventions: KAF156, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Asthma
Interventions: Budesonide, albuterol, Ipratropium bromide, Prednisone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: East Meadow, New York • Queens, New York • The Bronx, New York

Conditions: HIV Infections
Interventions: GSK3640254, Placebo, Moxifloxacin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma, Neuroendocrine Carcinoma, Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions: Cisplatin, Etoposide, Veliparib, Placebo; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 428
States / cities: Loma Linda, California • Palo Alto, California • Aurora, Colorado + 279 more

Conditions: Epilepsy, Lennox-Gastaut Syndrome
Interventions: GWP42003-P 20 mg/kg/day Dose, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 55 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 17
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more

Search by objective public record fields.

Determining How Quickly Progesterone Slows LH Pulse Frequency

ONO-7746 Study in Healthy Adult Subjects

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.

Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel

Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo

Differentiating the Effects of Substance P and Beta-endorphin

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Acupuncture Therapy for Pediatric Disorders of Gut-Brain Interaction

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

Neuromodulation of Mood Switch Circuitry in Bipolar Disorder

Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)

Digoxin In Treatment of Alcohol Associated Hepatitis

Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction

A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Interstitial Cystitis

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults